GlassScriptPhysician profile
Jenny Blanco
NPI 1295070654
$1,563.74
in general payments reported to CMS, 2019-2025
26 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $492 · 2022: $289 · 2023: $471 · 2024: $163 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $424.11 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $153.47 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $121.84 | 2025 | Rexulti |
| Ipsen Biopharmaceuticals, INC | $107.87 | 2023-2024 | Onivyde, Somatuline Depot |
| Pfizer INC. | $97.02 | 2022-2024 | |
| Incyte Corporation | $78.94 | 2022-2023 | Jakafi |
| Lilly USA, LLC | $62.16 | 2022-2023 | Jaypirca, Verzenio, Retevmo |
| Seagen INC. | $57.58 | 2022-2023 | Tivdak, Padcev |
| Astellas Pharma US INC | $47.95 | 2022-2023 | Padcev |
| Taiho Oncology, INC. | $41.75 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $34.28 | 2022-2023 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $33.20 | 2022 | |
| Amgen INC. | $31.16 | 2021-2022 | |
| Medtronic, INC. | $27.40 | 2021 | |
| Abbvie INC. | $27.19 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $22.77 | 2024 | Tecentriq, Rozlytrek, Alecensa |
| Acrotech Biopharma INC. | $22.09 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $21.56 | 2024 | Sancuso |
| Genentech, INC. | $21.33 | 2023 | Tecentriq |
| Takeda Pharmaceuticals U.S.A., INC. | $20.79 | 2023 | Vpriv |
| Astrazeneca Pharmaceuticals LP | $20.08 | 2023 | |
| Tersera Therapeutics LLC | $19.67 | 2023 | Zoladex |
| Daiichi Sankyo INC. | $18.86 | 2024 | Enhertu |
| Apellis Pharmaceuticals, INC. | $17.64 | 2023 | Empaveli |
| Deciphera Pharmaceuticals INC. | $16.94 | 2023 | Qinlock |
| Eisai INC. | $16.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Blanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.